Device Hematology

Qunatra Qplus System

Payments companies reported to CMS as associated with Qunatra Qplus System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$146Kassociated payments (2023-2025)
349clinicians with associated payments
1company reporting

By year

2024 $101K
2025 $45K

Payments reported as associated with Qunatra Qplus System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Anesthesiology $45K
Critical Care Medicine (Anesthesiology) $32K
Thoracic Surgery (Cardiothoracic Vascular Surgery) $21K
Anatomic Pathology & Clinical Pathology $14K
Emergency Medicine $7,916
Public Health & General Preventive Medicine $4,497

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Qunatra Qplus System

These are the largest totals companies reported as associated with Qunatra Qplus System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Jonathan Chow Washington, DC Critical Care Medicine (Anesthesiology) $27,907.07
Melissa Burger Dallas, TX Anesthesiology $26,301.53
Asad Shah Laguna Hills, CA Thoracic Surgery (Cardiothoracic Vascular Surgery) $18,691.99
Joseph Griggs Albuquerque, NM Anatomic Pathology & Clinical Pathology $12,393.23
Dallas Hack Sevierville, TN Public Health & General Preventive Medicine $4,497.48
Joseph Roderique Lakeland, FL Anesthesiology $4,063.70
Kevin Ward Ann Arbor, MI Emergency Medicine $4,042.84
Nathan White Seattle, WA Emergency Medicine $3,806.93
Michael Mazzeffi Charlottesville, VA Critical Care Medicine (Anesthesiology) $3,224.83
Joseph Rappold Portland, ME Surgical Critical Care $3,139.90

Prescribed Qunatra Qplus System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.